NASTORAZEPIDE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H36N4O5
Molecular Weight	520.6199
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)C(=O)CN1C2=CC=CC=C2N(C[C@@H](NC(=O)NC3=CC(=CC=C3)C(O)=O)C1=O)C4CCCCC4

InChI

InChIKey=VIJCCFFEBCOOIE-JOCHJYFZSA-N

InChI=1S/C29H36N4O5/c1-29(2,3)25(34)18-33-24-15-8-7-14-23(24)32(21-12-5-4-6-13-21)17-22(26(33)35)31-28(38)30-20-11-9-10-19(16-20)27(36)37/h7-11,14-16,21-22H,4-6,12-13,17-18H2,1-3H3,(H,36,37)(H2,30,31,38)/t22-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C29H36N4O5
Molecular Weight	520.6199
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20006921
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800016682 | http://www.zeria.co.jp/english/comp/co_0501.html |

Nastorazepide (Z-360) is a selective, orally available, gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells. It is currently under development as a therapeutic drug for pancreatic cancer, gastroesophageal reflux disease and peptic ulcers. The most commonly reported adverse events were nausea, abdominal pain, vomiting and fatigue.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cholecystokinin B receptor 9 Target ID: CHEMBL298 Sources: http://www.zeria.co.jp/english/comp/co_0501.html	Antagonist 2849		0.47 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Pancreatic cancer 98 Sources: http://www.zeria.co.jp/english/comp/co_0501.html http://adisinsight.springer.com/drugs/800016682 https://www.ncbi.nlm.nih.gov/pubmed/20006921	Primary	Phase II 1147	Unknown Approved Use Unknown
Metastatic pancreatic adenocarcinoma 5 Sources: https://clinicaltrials.gov/ct2/show/NCT02117258 https://www.ncbi.nlm.nih.gov/pubmed/17901954	Primary	Phase II 1147	Unknown Approved Use Unknown
Peptic ulcer 72 Sources: DOI: 10.1016/S0016-5085(08)81545-4 http://www.pharmacodia.com/web/drug/1_1566.html	Primary	Phase I 438	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
4434 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20006921/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:		NASTORAZEPIDE CALCIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6756 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20006921/	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:		NASTORAZEPIDE CALCIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
18600 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20006921/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:		NASTORAZEPIDE CALCIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
24030 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20006921/	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:		NASTORAZEPIDE CALCIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20006921/	120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered:		NASTORAZEPIDE CALCIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20006921/	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:		NASTORAZEPIDE CALCIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 inhibitor 2252	inducer 440 inhibitor 2438	inducer 109 inhibitor 2507 substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C8 1057 CYP1A2 2153 CYP2A6 879 CYP2B6 926 CYP2C19 2057 CYP2E1 1060	P-gp 2052	CYP2A6 86 CYP2C19 329 CYP1A2 832

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inducer 1966 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP2A6 911	inducer 1966 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP2A6 911	inhibitor 4027 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP2C19 2141	inducer 1966 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP2C9 2497	inducer 1966 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP2D6 2546	inducer 1966 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP3A4 2633	inducer 1966 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	weak [IC50 10 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_236/_article/-char/ja/	yes [IC50 1 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=363681355	no
CYP2D6 1388	substrate 4014 Sources: https://www.jstage.jst.go.jp/article/jssxmeeting/17/0/17_0_239/_article/-char/ja/	yes

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P00BFND	https://www.1pchem.com/search?query=1P00BFND
BLD Pharm	BD630531	http://www.bldpharm.com/search/Search.html?keyword=BD630531
Chem Scene	CS-5383	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5383
ChemShuttle	171845	https://www.chemshuttle.com/catalogsearch/result/?q=171845
eMolecules	275077049	https://orderbb.emolecules.com/search/#?query=275077049
eMolecules	303152888	https://orderbb.emolecules.com/search/#?query=303152888
eMolecules	75542249	https://orderbb.emolecules.com/search/#?query=75542249
eMolecules	76738726	https://orderbb.emolecules.com/search/#?query=76738726
eNovation Chemicals	D548072	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D548072&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-1006717196	https://mcule.com/MCULE-1006717196/
MedChem Express	HY-17617	https://www.medchemexpress.com/search.html?q=HY-17617&ft=&fa=&fp=
Molnova	M13278	https://www.molnova.com/en/serch-list.html?keywords=M13278
MolPort	MolPort-046-417-193	https://www.molport.com/shop/molecule-link/MolPort-046-417-193

PubMed

Title	Date	PubMed
Potential clinical indications for a CCK2 receptor antagonist.	2016-12	27710813
CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.	2011-10-24	21839751
Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice.	2010-10-28	20979661

Patents

Sample Use Guides

In Vivo Use Guide

60, 120 or 240 mg, twice daily (28-day cycle).

Route of Administration: Oral

In Vitro Use Guide

In PANC-1 cells, gemcitabineinduced expression of HIF-1alpha gene was suppressed by treatment with 0.1 μM Z-360.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:38:39 GMT 2025` Edited by `admin` on `Mon Mar 31 22:38:39 GMT 2025`
Record UNII	R22TMY97SG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NASTORAZEPIDE

Official Name

English

nastorazepide [INN]

Preferred Name

English

Z-360 FREE ACID

Code

English

BENZOIC ACID, 3-(((((3R)-5-CYCLOHEXYL-1-(3,3-DIMETHYL-2-OXOBUTYL)-2,3,4,5-TETRAHYDRO-2-OXO-1H-1,5-BENZODIAZEPIN-3-YL)AMINO)CARBONYL)AMINO)-

Systematic Name

English

Nastorazepide [WHO-DD]

Common Name

English

R-(-)-Z-360 FREE ACID

Code

English

Code System Code Type Description

PUBCHEM

9872609